Metastatic lesion location and avidity on baseline PSMA PET/CT as predictor of duration of Lu177 treatment in men with metastatic castrate resistant prostate cancer.
Retrospective review finds PSMA uptake predictive of treatment duration in mCRPC, suggesting tailored therapy cycles.
Key Points
This study aims to clarify how PSMA uptake on PET/CT predicts the duration of Lu-177 treatment in men with metastatic castrate-resistant prostate cancer.
Conducted a retrospective review of patients receiving Lu-177 therapy.
Analyzed pretreatment PSMA PET scans to identify lesions and quantify uptake values.
Stratified patients based on treatment cycles (>3 vs. ≤3 Lu-177 cycles).
Used Fisher’s exact test to assess associations between uptake metrics and treatment duration.
Higher maximum SUV in bone and lymph node metastases was associated with more than three treatment cycles.
Mean SUV values did not correlate with the number of treatment cycles.
Individuals with high PSMA avidity potentially benefit more from extended treatment.